查克马 (Papio ursinus) 的血栓生成能力:对血静性疾病模型的含义
J Joubert1,2, S M Meiring3,4, W J Janse van Rensburg5
1Department of Haematology and Cell Biology, School of Pathology, Faculty of Health Sciences, University of the Free State, 205 Nelson Mandela Drive, PO Box 339 (G2), Bloemfontein, 9300, South Africa. joubertj@ufs.ac.za.
Scientific reports
|December 27, 2023
概括
查克马的整体血栓生成率高于人类,尤其是女性. 血液静止的这种差异对于设计临床前研究和评估模型中的新药至关重要.
科学领域:
- 血液静止和血栓形成研究
- 临床前动物模型
- 药理学和药物开发领域
背景情况:
- 模型对于研究血静性疾病和测试新疗法至关重要.
- 血栓激素生成是血液静止的一个关键因素,也是药物开发的关键目标.
- 了解血栓生成中的特定物种差异对于准确的临床前研究至关重要.
研究的目的:
- 描述查克马 (Papio ursinus) 的血栓生成特征.
- 为了比较的血栓生成与人体血参考间隔.
- 为了研究性别和ABO血型对血栓生成的影响.
主要方法:
- 评估了血栓生成曲线,滞后时间,峰值高度,时间到峰值,速度指数和内源性血栓潜力 (ETP).
- 使用了低度的组织因子 (1 pM) 和脂.
- 对比了40只成年Chacma和正常人体血的结果,分析了性别和ABO血型的影响.
主要成果:
- 巴的滞后时间在人类的参考间隔内.
- 与人类相比,大多数的峰值时间较长,峰值高度和速度指数明显较低.
- 几乎所有的 (97.5%) 显示出比人类更高的内源性血栓潜在 (ETPs),表明总体产生更大的血栓.
- ABO 血型没有显著影响,但雄性比雌性血生成能力较弱.
结论:
- 查克马的总体内源性血栓生成潜力明显高于人类.
- 与雄性相比,雌性比雄性更强地产生血栓激素.
- 在设计模型实验和治疗评估时,必须考虑这些特定物种的静血差异.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
702
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
702
Disorders of Hemostasis
922
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
922


